These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 26666230

  • 1. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
    Calsolaro V, Edison P.
    CNS Drugs; 2015 Dec; 29(12):1023-39. PubMed ID: 26666230
    [Abstract] [Full Text] [Related]

  • 2. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J, Blunt E, Gupta D, Edison P.
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [Abstract] [Full Text] [Related]

  • 3. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
    Hölscher C.
    J Endocrinol; 2014 Apr; 221(1):T31-41. PubMed ID: 23999914
    [Abstract] [Full Text] [Related]

  • 4. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Sheng Li Xue Bao; 2014 Oct 25; 66(5):497-510. PubMed ID: 25331995
    [Abstract] [Full Text] [Related]

  • 5. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N, García-Arnés JA, Gómez-Huelgas R, Valdivielso-Felices P, García-Arias C, González-Santos P.
    Rev Neurol; 2014 Dec 01; 59(11):517-24. PubMed ID: 25418147
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
    McClean PL, Gault VA, Harriott P, Hölscher C.
    Eur J Pharmacol; 2010 Mar 25; 630(1-3):158-62. PubMed ID: 20035739
    [Abstract] [Full Text] [Related]

  • 9. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL, Hölscher C.
    Neuropharmacology; 2014 Jan 25; 76 Pt A():57-67. PubMed ID: 23973293
    [Abstract] [Full Text] [Related]

  • 10. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C.
    Biochem Soc Trans; 2011 Aug 25; 39(4):891-7. PubMed ID: 21787319
    [Abstract] [Full Text] [Related]

  • 11. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
    Holscher C.
    Recent Pat CNS Drug Discov; 2010 Jun 25; 5(2):109-17. PubMed ID: 20337586
    [Abstract] [Full Text] [Related]

  • 12. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
    Batista AF, Bodart-Santos V, De Felice FG, Ferreira ST.
    CNS Drugs; 2019 Mar 25; 33(3):209-223. PubMed ID: 30511349
    [Abstract] [Full Text] [Related]

  • 13. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
    Hunter K, Hölscher C.
    BMC Neurosci; 2012 Mar 23; 13():33. PubMed ID: 22443187
    [Abstract] [Full Text] [Related]

  • 14. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
    Kopp KO, Glotfelty EJ, Li Y, Greig NH.
    Pharmacol Res; 2022 Dec 23; 186():106550. PubMed ID: 36372278
    [Abstract] [Full Text] [Related]

  • 15. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C.
    Neuropharmacology; 2018 Jul 01; 136(Pt B):251-259. PubMed ID: 29402504
    [Abstract] [Full Text] [Related]

  • 16. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
    Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.
    Expert Opin Ther Targets; 2011 Oct 01; 15(10):1153-62. PubMed ID: 21749267
    [Abstract] [Full Text] [Related]

  • 17. The role of GLP-1 in neuronal activity and neurodegeneration.
    Hölscher C.
    Vitam Horm; 2010 Oct 01; 84():331-54. PubMed ID: 21094907
    [Abstract] [Full Text] [Related]

  • 18. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.
    Hölscher C.
    Br J Pharmacol; 2022 Feb 01; 179(4):695-714. PubMed ID: 33900631
    [Abstract] [Full Text] [Related]

  • 19. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease.
    Perry T, Greig NH.
    J Alzheimers Dis; 2002 Dec 01; 4(6):487-96. PubMed ID: 12515900
    [Abstract] [Full Text] [Related]

  • 20. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J, Gallwitz B.
    Diabetes Obes Metab; 2014 Aug 01; 16(8):673-88. PubMed ID: 24373150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.